Other featured articles
Shame Won’t Solve America’s Obesity Crisis: How Congress Can Help
If saving lives is the objective, then logic, clinical evidence and compassion dictate that Medicare should pay for preventing and treating obesity, starting now.
CMS’s Alzheimer’s Coverage Policy Will Inhibit Access and Discourage Innovation
Individuals in underserved communities have to travel long distances, well beyond the 30-minute standard, to access clinical trial sites for Aduhelm.
During the Height of the Opioid Epidemic, the Out-of-Pocket Price of Naloxone Increased by Over 500%
A jump in the out-of-pocket price of naloxone has likely made the lifesaving drug too expensive for most uninsured Americans.
Reforming the Medicare Part D Benefit Design: Financial Implications for Beneficiaries, Private Plans, Drug Manufacturers, and the Federal Government
Researchers evaluate prescription drug claims from Medicare Part D beneficiaries to evaluate the current spending distribution.
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.